In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Cabazitaxel versus docetaxel in men with advanced, hormone-resistant prostate cancer
In a nutshell The authors aimed to determine whether cabazitaxel (Jevtana) was superior to docetaxel (Taxotere) in improving overall survival in patients with advanced, hormone-resistant prostate cancer who had not received previous treatment with chemotherapy. The authors concluded that cabazitaxel was not superior...
Read MoreCurrent treatment options for patients with relapsed or difficult to treat mantle cell lymphoma
In a nutshell This review explores the current treatments for patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma. Patients with relapsed MCL generally have poor outcomes. These patients with relapsed or difficult to treat (refractory) MCL have...
Read MoreA review of venetoclax for previously treated CLL
In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...
Read MoreAn analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer
In a nutshell This study aimed to determine which patients benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. Some background A main treatment option for prostate cancer is androgen deprivation...
Read MoreLenalidomide treatment for patients with relapsed diffuse large B-cell lymphoma
In a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...
Read MoreEffectiveness of venetoclax in relapsed or refractory multiple myeloma
In a nutshell This paper studied the effectiveness of venetoclax (Venclexta) for the treatment of relapsed or refractory multiple myeloma. Venetoclax at a daily dose up to 1200 mg showed promise in treating patients with relapsed or refractory multiple myeloma with the t(11;14) genetic mutation. Some background Multiple myeloma is a cancer...
Read MoreIdentifying which patients with ES-SCLC would benefit from radiation
In a nutshell This trial looked at factors which would help predict whether aggressive radiation would be beneficial to patients with extensive stage small cell lung cancer who have progressed passed chemotherapy. The authors concluded that patients with less than three metastases (spread of cancer) would benefit most. Some background...
Read MoreThe use of a blood test to predict future outcomes for patients with relapsed diffuse large B-cell lymphoma
In a nutshell This study looked at how effective a blood test was at predicting future outcomes in patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that the lymphocyte-to-monocyte ratio blood test is very effective at predicting future outcomes for patients with relapsed or difficult to treat diffuse large...
Read MoreLooking for patients with refractory multiple myeloma to test blinatumomab after autologous stem cell transplantation
In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read MoreLooking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy
In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...
Read MoreCarfilzomib versus bortezomib in multiple myeloma that has not responded to treatment
In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...
Read More